NeuroPace Raises 2026 Revenue Guidance to $99M-$101M After Strong Q1 Results
NPCE has more than doubled off its 52-week low of $7.563.
Summary
NeuroPace reported strong first-quarter 2026 financial results, with total revenue reaching $22.1 million, representing 20.1% year-over-year growth, and an improved adjusted EBITDA loss. Building on this performance, the company raised its full-year 2026 revenue guidance to a range of $99 million to $101 million, up from the prior $98 million to $100 million. This positive update signals management's increased confidence in its operational execution and market demand for its RNS System, which achieved new highs in active prescribers and patient pipeline. The raised outlook is a material positive catalyst for the stock, potentially leading to upward revisions in analyst estimates. Investors will now watch for the potential mid-2026 FDA approval of the NAUTILUS PMA-Supplement for idiopathic generalized epilepsy, which is expected to further contribute to growth.
At the time of this announcement, NPCE was trading at $15.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $536.4M. The 52-week trading range was $7.56 to $19.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.